A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine
IntroductionFor complete or functional cure of hepatitis B virus (HBV) infection, application of immunotherapy is now being attempted. Recently, we reported that a 6-mer hepatitis B virus (HBV)-derived peptide, Poly6, exerts a strong anticancer effect in tumor-implanted mice through inducible nitric...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1155637/full |
| _version_ | 1797813672816410624 |
|---|---|
| author | Yu-Min Choi Dong Hyun Kim Junghwa Jang Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim |
| author_facet | Yu-Min Choi Dong Hyun Kim Junghwa Jang Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim |
| author_sort | Yu-Min Choi |
| collection | DOAJ |
| description | IntroductionFor complete or functional cure of hepatitis B virus (HBV) infection, application of immunotherapy is now being attempted. Recently, we reported that a 6-mer hepatitis B virus (HBV)-derived peptide, Poly6, exerts a strong anticancer effect in tumor-implanted mice through inducible nitric oxide synthase (iNOS)-producing DCs (Tip-DCs) in a type 1 interferon (IFN-I)-dependent manner, suggesting its potential as a vaccine adjuvant.MethodsIn this study, we explored the potential of Poly6 in combination with HBsAg as a therapeutic vaccine against hepatitis B virus infection. We investigated the immunotherapeutic potential of Poly6 combined with HBsAg vaccination against hepatitis B virus infection in C57BL/6 mice or an HBV transgenic mouse model.ResultsIn C57BL/6 mice, Poly6 enhanced DC maturation and DC migration capacity in an IFN-I-dependent manner. Moreover, the addition of Poly6 to alum in combination with HBsAg also led to enhanced HBsAg-specific cell-mediated immune (CMI) responses, suggesting its potential as an adjuvant of HBsAg-based vaccines. In HBV transgenic mice, vaccination with Poly6 combined with HBsAg exerted a strong anti-HBV effect via induction of HBV-specific humoral and cell-mediated immune responses. In addition, it also induced HBV-specific effector memory T cells (TEM).DiscussionOur data indicated that vaccination with Poly6 in combination with HBsAg exerts an anti-HBV effect in HBV transgenic mice, which is mainly mediated by HBV-specific CMI and humoral immune responses via IFN-I-dependent DC activation, suggesting the feasibility of Poly6 as an adjuvant for an HBV therapeutic vaccine. |
| first_indexed | 2024-03-13T07:56:17Z |
| format | Article |
| id | doaj.art-90c20610facd42d78d3066b0fddbc4d9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T07:56:17Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-90c20610facd42d78d3066b0fddbc4d92023-06-02T04:45:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-06-011410.3389/fimmu.2023.11556371155637A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccineYu-Min Choi0Dong Hyun Kim1Junghwa Jang2Bum-Joon Kim3Bum-Joon Kim4Bum-Joon Kim5Bum-Joon Kim6Bum-Joon Kim7Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of KoreaDepartment of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of KoreaLiver Research Institute, College of Medicine, Seoul National University, Seoul, Republic of KoreaCancer Research Institute, College of Medicine, Seoul National University, Seoul, Republic of KoreaDepartment of Microbiology and Immunology, Seoul National University Medical Research Center (SNUMRC), Seoul, Republic of KoreaIntroductionFor complete or functional cure of hepatitis B virus (HBV) infection, application of immunotherapy is now being attempted. Recently, we reported that a 6-mer hepatitis B virus (HBV)-derived peptide, Poly6, exerts a strong anticancer effect in tumor-implanted mice through inducible nitric oxide synthase (iNOS)-producing DCs (Tip-DCs) in a type 1 interferon (IFN-I)-dependent manner, suggesting its potential as a vaccine adjuvant.MethodsIn this study, we explored the potential of Poly6 in combination with HBsAg as a therapeutic vaccine against hepatitis B virus infection. We investigated the immunotherapeutic potential of Poly6 combined with HBsAg vaccination against hepatitis B virus infection in C57BL/6 mice or an HBV transgenic mouse model.ResultsIn C57BL/6 mice, Poly6 enhanced DC maturation and DC migration capacity in an IFN-I-dependent manner. Moreover, the addition of Poly6 to alum in combination with HBsAg also led to enhanced HBsAg-specific cell-mediated immune (CMI) responses, suggesting its potential as an adjuvant of HBsAg-based vaccines. In HBV transgenic mice, vaccination with Poly6 combined with HBsAg exerted a strong anti-HBV effect via induction of HBV-specific humoral and cell-mediated immune responses. In addition, it also induced HBV-specific effector memory T cells (TEM).DiscussionOur data indicated that vaccination with Poly6 in combination with HBsAg exerts an anti-HBV effect in HBV transgenic mice, which is mainly mediated by HBV-specific CMI and humoral immune responses via IFN-I-dependent DC activation, suggesting the feasibility of Poly6 as an adjuvant for an HBV therapeutic vaccine.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1155637/fullhepatitis B virus (HBV)therapeutic vaccinationadjuvanttype 1 interferon (IFN-I)(HBV)-derived peptidePoly6 |
| spellingShingle | Yu-Min Choi Dong Hyun Kim Junghwa Jang Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim Bum-Joon Kim A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine Frontiers in Immunology hepatitis B virus (HBV) therapeutic vaccination adjuvant type 1 interferon (IFN-I) (HBV)-derived peptide Poly6 |
| title | A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine |
| title_full | A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine |
| title_fullStr | A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine |
| title_full_unstemmed | A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine |
| title_short | A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine |
| title_sort | hepatitis b virus derived peptide combined with hbsag exerts an anti hbv effect in an hbv transgenic mouse model as a therapeutic vaccine |
| topic | hepatitis B virus (HBV) therapeutic vaccination adjuvant type 1 interferon (IFN-I) (HBV)-derived peptide Poly6 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1155637/full |
| work_keys_str_mv | AT yuminchoi ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT donghyunkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT junghwajang ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim ahepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT yuminchoi hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT donghyunkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT junghwajang hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine AT bumjoonkim hepatitisbvirusderivedpeptidecombinedwithhbsagexertsanantihbveffectinanhbvtransgenicmousemodelasatherapeuticvaccine |